HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Samoszuk, M. K. Articles by Slater, L. M. Search for Related Content PubMed PubMed Citation Articles by Samoszuk, M. K. Articles by Slater, L. M.

Radioimmunodetection of Hodgkin's Disease and Non-Hodgkin's Lymphomas with Monoclonal Antibody to Eosinophil Peroxidase

Departments of Pathology, Nuclear Medicine and Medicine, University of California, Irvine, California

Correspondence: For correspondence and reprints contact: Michael Samoszuk, MD, Pathology Department, Medical Sciences I, D-440, University of California, Irvine, CA 92717.

ABSTRACT

The purpose of this study was to determine if a radiolabeled murine monoclonal antibody (EOS) directed against eosunophil peroxidase would localize specifically to tumor sites in patients with lymphomas infiltrated by eosinophils. Ten patients with Hodgkin's disease and eosinophilia, three patients with non-Hodgkin's lymphomas and eosunophilia and five control patients received an intravenous injection of 3–10 mg of EOS antibody radiolabeled with 74–155 MBq (2.0–4.2 mCi) of ¹¹¹In. At intervals of 24, 48 and 72 hr after injection, gamma camera images were obtained along with blood and urine specimens and the imaging results were correlated with the results of other staging modalities. As early as 24 hr after antibody injection, there was clear visualization of identifiable sites of lymphoma with eosinophilia greater than 1 cm in size, including the spleen, bone marrow and lymph nodes. Although EOS also localized nonspecifically to the liver and, in some patients, to the nasopharynx, there was no appreciable uptake in normal bone marrow, spleen, uninvolved lymph nodes, lymphomas without eosinophilia or various other pathologic conditions without eosinophilia. Except for transient pain at tumor sites in three patients, no adverse reactions were noted. We conclude that a radiolabeled monoclonal antibody directed against eosinophil peroxidase localizes to lymphoma sites infiltrated by eosinophils.

This article has been cited by other articles:

				R. D. Blumenthal, M. Samoszuk, A. P. Taylor, G. Brown, R. Alisauskas, and D. M. Goldenberg Degranulating Eosinophils in Human Endometriosis Am. J. Pathol., May 1, 2000; 156(5): 1581 - 1588. [Abstract] [Full Text] [PDF]